Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11039434 | 0.98 | PRMT1 (0.68) | PRMT1ADRA1ALMNAMAPK1NFKB1 | |
| SCHEMBL9307514 | 0.98 | PRMT1 (0.68) | PRMT1ADRA1ALMNAMAPK1NFKB1 | |
| SCHEMBL2028710 | 0.98 | PRMT1 (0.68) | PRMT1ADRA1ALMNAMAPK1NFKB1 | |
| SCHEMBL2035521 | 0.93 | PRMT1 (0.54) | PRMT1ADRA1ALMNAMAPK1NFKB1 | |
| SCHEMBL19683940 | 0.85 | PRMT1 (0.44) | PRMT1ADRA1AMAPK1MEN1ALDH1A1 | |
| SCHEMBL1837224 | 0.84 | KDM4E (0.48) | PRMT1LMNAMAPK1NFKB1TSHR | |
| Hydrochloric Acid SCHEMBL29935745 | 0.83 | PRMT1 (0.43) | PRMT1ADRA1ALMNAMAPK1MEN1 | |
| SCHEMBL11445239 | 0.83 | PRMT1 (0.48) | PRMT1ADRA1AMAPK1MEN1ALDH1A1 | |
| SCHEMBL440563 | 0.82 | — | — | |
| SCHEMBL21114363 | 0.82 | ECE1 (0.50) | PRMT1ADRA1ALMNANFKB1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025098391-A9 | SELECTIVE DRUG RELEASE FROM CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | NONA BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2026-04-30 | — | — | WO | disclosed |
| US-20260112616-A1 | ADVANCED ELECTROLYTE SYSTEMS WITH SPECIALIZED ADDITIVES FOR IMPROVING PERFORMANCE OF LITHIUM-SULFUR BATTERIES | LYTEN INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | disclosed |
| US-20250332268-A1 | CONJUGATE AND COMPOSITION AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-10-30 | — | — | US | disclosed |
| WO-2025098391-A1 | SELECTIVE DRUG RELEASE FROM CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | NONA BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2025-05-15 | — | — | WO | disclosed |
| CN-119306732-B | Bioactive substance conjugate, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025082461-A1 | POLYPEPTIDE, BIOACTIVE CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 优洛生物(上海)有限公司 | 2025-04-24 | — | — | WO | disclosed |
| WO-2025077871-A1 | CONJUGATE, DRUG CONJUGATE AND COMPOSITION, AND PREPARATION METHOD AND USE | 苏州瑞博生物技术股份有限公司 | 2025-04-17 | — | — | WO | disclosed |
| CN-119818694-A | Use of conjugates in medicaments for diagnosing or treating triple negative breast cancer and related diseases | 苏州瑞博生物技术股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20130002757-A1 | INK SET AND DROPLET EJECTION APPARATUS USING THE INK SET | SEIKO EPSON CORPORATION (JP) | 2013-01-03 | — | — | US | disclosed |
| CN-102643569-A | Ink composition and ink jet recording method using same | SEIKO EPSON CORP | 2012-08-22 | — | — | CN | disclosed |
| US-20120202019-A1 | AZO COMPOUNDS, INK COMPOSITIONS, AND COLORED BODIES | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2012-08-09 | — | — | US | disclosed |
| CN-102575109-A | Azo compounds, ink compositions, and colored bodies | NIPPON KAYAKU KK | 2012-07-11 | — | — | CN | disclosed |
| EP-2471874-A1 | AZO COMPOUNDS, INK COMPOSITIONS, AND COLORED BODIES | Nippon Kayaku Kabushiki Kaisha (JP) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011143209-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-11-17 | — | — | WO | disclosed |
| EP-2346870-A1 | 18F-LABELLED FOLATES AS PET RADIOTRACERS | Merck & Cie (CH) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010040854-A1 | 18F-LABELLED FOLATES AS PET RADIOTRACERS | MERCK EPROVA AG (CH) | 2010-04-15 | — | — | WO | disclosed |
| US-6277991-B1 | FOR TREATMENT OF MIGRAINE, NON-INSULIN DEPENDENT DIABETES MELLITUS, SEPSIS, INFLAMMATION, INCONTINENCE, VASOMOTOR DISTURBANCES SUCH AS HOT FLUSHES OR HOT FLASHES | NOVO NORDISK A/S (DK) | 2001-08-21 | — | — | US | disclosed |
| EP-0021883-A2 | N-acyl-amino acid derivatives and pharmaceutical compositions containing them, intermediates and starting compounds | MERRELL TORAUDE ET COMPAGNIE (FR) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332268-A1 | CONJUGATE AND COMPOSITION AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | HADHB, LITAF, EZR | PRMT1 3063/4885ADRA1A 3687/4885LMNA 2408/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | PRMT1 1010/4885ADRA1A 729/4885LMNA 1520/4885 |
| US-20260112616-A1 | ADVANCED ELECTROLYTE SYSTEMS WITH SPECIALIZED ADDITIVES FOR IMPROVING PERFORMANCE OF LITHIUM-SULFUR BATTERIES | MEF2D, LEF1, KCNN2 | PRMT1 654/4885ADRA1A 4183/4885LMNA 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.